TD Cowen analyst Joshua Jennings reiterated a Buy rating and $135.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented: "The Stage is Set for a Stronger 2H; We expect ABT to make a return to +M-HSD% sales growth in 3Q26 alongside multiple business recoveries (Core Dx & Nutrition) and accelerations (Cancer Dx and Electrophysiology). We tweak our 3Q/4Q EP estimates to account for broad LAAC market softness, but strong P&L results and an in-line 3Q with multiple catalysts playing out should keep guidance on the table and allow the stock to work higher."

For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.

Shares of Abbott Labs closed at $104.68 yesterday.